Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OKYO Pharma Limited (OKYO)
USD1.48
-0.10 (-6.08%)
GB NASDAQ Healthcare Biotechnology
Address
55 Park Lane W1K 1NA
London, GB
London, GB
CEO
Robert J. Dempsey
Website
okyopharma.com
IPO
2022-05-17
CIK 1849296 ISIN GG00BMFG5F62
Also trades on
London Stock Exchange · OKYO.L (GBp)
NASDAQ Capital Market · OKYO (USD)
Other OTC · EMMLF (USD)
Description
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
News Sentiment (7d)
6 articles
- Forte Biosciences shares surge after positive phase 1b vitiligo results Proactive Investors - Finance
- OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain GlobeNewsWire
- OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain Proactive Investors
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.48
-0.10 (-6.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
66.6K
Beta
0.02
Float Shares
20.77M
Free Float %
54.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.29% | +5.21% | +9.94% | +0.29% | -12.50% | -17.15% | -2.00% | +9.94% | -52.62% | -52.62% | -52.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
1.48
Low
7.00
+371.7%
Consensus
7.00
+371.7%
Median
7.00
+371.7%
High
7.00
+371.7%
DCF (Levered)
0.04
-97.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
7.00
+371.7%
|
| All Time | 1 |
7.00
+371.7%
|
Quality scores
Altman Z-Score
-46.94
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-19,900.0% Q3'25: -17,175.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'25: +134.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+34.6% Q3'25: +45.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q3'25: -0.02× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2025 actual |
Mar 2026 1 EPS Ana. |
Mar 2027 1 EPS Ana. |
Mar 2028 2 Rev. Ana. 1 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
11.00M
11.00M – 11.00M
|
32.20M
32.20M – 32.20M
+192.7% YoY
|
55.20M
55.20M – 55.20M
+71.4% YoY
|
| EBITDA |
-7.08M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-7.09M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-4.71M
est: -5.92M (+20.5%)
|
-3.95M
-4.64M – -3.26M
+33.3% YoY
|
-7.90M
-7.90M – -7.90M
-100.0% YoY
|
-23.30M
-23.30M – -23.30M
-195.0% YoY
|
-20.53M
-20.53M – -20.53M
+11.9% YoY
|
-11.06M
-11.06M – -11.06M
+46.2% YoY
|
| SGA |
4.93M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.12
est: -0.15 (+20.0%)
|
-0.10
-0.12 – -0.08
+33.3% YoY
|
-0.20
-0.20 – -0.20
-100.0% YoY
|
-0.59
-0.59 – -0.59
-195.0% YoY
|
-0.52
-0.52 – -0.52
+11.9% YoY
|
-0.28
-0.28 – -0.28
+46.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
10
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2030-01-02 | Dempsey Robert John | Director / Officer | — | — | Options | 400,000 | 2.23 | 892.0K | 0 | D | ↗ |
| 2029-07-16 | JACOB GARY S | Director / Officer | — | — | Options | 89,356 | 2.75 | 245.7K | 0 | D | ↗ |
| 2029-03-25 | Shah Keeren Rameshchandra | Officer | — | — | Options | 31,250 | 1.50 | 46.9K | 0 | D | ↗ |
| 2029-03-25 | JACOB GARY S | Director / Officer | — | — | Options | 50,000 | 1.50 | 75.0K | 0 | D | ↗ |
| 2029-01-29 | Shah Keeren Rameshchandra | Officer | — | — | Options | 877 | 1.60 | 1.4K | 0 | D | ↗ |
| 2028-01-29 | JACOB GARY S | Director / Officer | — | — | Options | 102,564 | 1.60 | 164.1K | 0 | D | ↗ |
| 2027-10-20 | Shah Keeren Rameshchandra | Officer | — | — | Options | 21,250 | 1.57 | 33.4K | 0 | D | ↗ |
| 2027-03-14 | Shah Keeren Rameshchandra | Officer | — | — | Options | 25,193 | 2.13 | 53.7K | 0 | D | ↗ |
| 2027-03-14 | JACOB GARY S | Director / Officer | — | — | Options | 21,154 | 2.13 | 45.1K | 0 | D | ↗ |
| 2027-03-13 | Shah Keeren Rameshchandra | Officer | — | — | Options | 21,667 | 1.46 | 31.6K | 0 | D | ↗ |
| 2026-03-18 | Shah Keeren Rameshchandra | Officer | — | — | COMMON STOCK | 0 | 0.00 | — | 16,667 | D | ↗ |
| 2026-03-18 | JACOB GARY S | Director / Officer | — | — | COMMON STOCK | 0 | 0.00 | — | 108,920 | D | ↗ |
| 2026-03-18 | CERRONE GABRIELE M | Director / 10% Owner | — | — | COMMON STOCK | 0 | 0.00 | — | 10,526,416 | D | ↗ |
| 2025-03-13 | JACOB GARY S | Director / Officer | — | — | Options | 16,667 | 1.46 | 24.3K | 0 | D | ↗ |
| 2023-10-27 | CERRONE GABRIELE M | Director / Officer | J-Other | A | Ordinary Shares | 70,071 | 1.50 | 105.1K | 9,177,903 | — | ↗ |
| 2023-10-23 | CERRONE GABRIELE M | Director / Officer | J-Other | A | Ordinary Shares | 499,468 | 1.50 | 749.2K | 9,107,832 | — | ↗ |
| 2023-09-15 | BRANCACCIO JOHN P | Director | P-Purchase | A | Ordinary Shares | 16,670 | 1.50 | 25.0K | 16,670 | — | ↗ |
| 2022-05-19 | JACOB GARY S | Officer | P-Purchase | A | American Depositary Shares | 12,500 | 4.00 | 50.0K | 12,500 | — | ↗ |
| 2022-05-19 | CERRONE GABRIELE M | Officer | P-Purchase | A | Ordinary Shares | 5,800,000 | 0.08 | 440.8K | 548,981,215 | — | ↗ |
| 2022-05-17 | CERRONE GABRIELE M | Director / Officer / 10% Owner | P-Purchase | A | American Depositary Shares | 25,000 | 3.87 | 96.8K | 25,000 | — | ↗ |
| 2022-05-16 | Simon Willy Jules | Director | — | D | Option (right to buy) | 2,000,000 | 0.06 | 117.6K | 0 | — | ↗ |
| 2022-05-16 | Shah Keeren | Officer | — | D | Option (right to buy) | 300,000 | 0.20 | 60.8K | 0 | — | ↗ |
| 2022-05-16 | JACOB GARY S | Director / Officer | — | D | Option (right to buy) | 40,000,000 | 0.07 | 2.61M | 0 | — | ↗ |
| 2022-05-16 | Denoyer Bernard | Director | — | D | Option (right to buy) | 1,000,000 | 0.10 | 104.5K | 0 | — | ↗ |
| 2022-05-16 | CERRONE GABRIELE M | Director / Officer / 10% Owner | — | I | Ordinary Shares | 0 | 0.00 | — | 543,181,215 | — | ↗ |
| 2022-05-16 | BRANCACCIO JOHN P | Director | — | D | Option (right to buy) | 450,000 | 0.20 | 91.1K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
38.37M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gary S. Jacob | Chief Development Officer & Director | 450.0K | — |
| Robert J. Dempsey | Chief Executive Officer & Executive Director | 450.0K | male |
| Flavio Mantelli | Chief Medical Officer | — | — |
| Keeren Shah | Chief Financial Officer | — | female |
| Michael Paul Beck | Founder | — | male |
| Rajkumar Patil | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OKYO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
